Back to top
more

Apollo Endosurgery, Inc. (APEN)

(Delayed Data from NSDQ)

$3.54 USD

3.54
5,491

-0.28 (-7.33%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.95 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Omnicell (OMCL) to Expand EnlivenHealth Division With New Buyout

by Zacks Equity Research

Omnicell's (OMCL) $82-million buyout of MarkeTouch Media is likely to expand its Advanced Services portfolio.

Quest Diagnostics (DGX) Rides on Test Sales, Base Volume Gain

by Zacks Equity Research

Quest Diagnostics (DGX) continues to benefit from rapidly increasing molecular diagnostic testing volumes, driven by the massive spread of the new COVID-19 variant.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) given the strength in the diagnostics business and notable acquisition deals.

Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.

Phirbo's (PAHC) Rising Costs, Currency Headwind Ail Growth

by Zacks Equity Research

Though Phirbo (PAHC) has raised prices on selective products, these increases do not fully compensate for the higher cost of freight and labor materials.

Here's Why You Should Hold on to National Vision (EYE) for Now

by Zacks Equity Research

Investors are optimistic about National Vision (EYE), given new store growth for America's Best and Eyeglass World brands.

Apollo Endosurgery, Inc. (APEN) Moves 7% Higher: Will This Strength Last?

by Zacks Equity Research

Apollo Endosurgery, Inc. (APEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here's Why You Should Invest in Abbott (ABT) Stock Right Now

by Zacks Equity Research

Riding on current business growth and bullish near-term prospects, Abbott (ABT) is worth investing in for now.

    Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?

    by Zacks Equity Research

    Strength in end markets and significant contribution from COVID-response related revenues are driving Thermo Fisher's (TMO) top line.

      Omnicell (OMCL) Closes ReCept Holdings Acquisition Deal

      by Zacks Equity Research

      Omnicell's (OMCL) completed buyout of the renowned specialty pharmacy management services provider is likely to bolster its Advanced Services offering.

      Neogen (NEOG) Q2 Earnings Lag Estimates, Revenues Surpass

      by Zacks Equity Research

      Robust segmental performance and contributions from StandGuard & Soleris product lines drove the top line for Neogen (NEOG) in the second quarter of fiscal 2022.

      Here's Why You Should Hold on to ResMed (RMD) Stock for Now

      by Zacks Equity Research

      Investors are optimistic about ResMed's (RMD) strong sales in its mask product offering and growing uptake of its digital health solutions.

      Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

      by Zacks Equity Research

      Investors are optimistic about Bio-Rad (BIO) owing to robust segmental performances and a rebound in non-COVID businesses.

      Edwards Lifesciences (EW) at 52-Week High: What's Driving It?

      by Zacks Equity Research

      Robust performance across the Critical Care and TAVR businesses is driving the top line for Edwards Lifesciences (EW).

      Thermo Fisher (TMO) Releases New Update for Omicron Detection

      by Zacks Equity Research

      Thermo Fisher's (TMO) TaqMan SARS-CoV-2 Mutation Panel currently offers direct identification of the novel variant of concern.

      Medtronic (MDT) to Gain From Expanded Medicare Coverage for CGM

      by Zacks Equity Research

      CMS' expanded Medicare coverage includes continuous glucose monitors that can be integrated with Medtronic's (MDT) insulin pumps.

      Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear

      by Zacks Equity Research

      Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

      Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

      by Zacks Equity Research

      Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.

      Zimmer Biomet (ZBH) Americas Business Slows Down Amid Pandemic

      by Zacks Equity Research

      Zimmer Biomet (ZBH) continues to face COVID-induced challenges and market pressure.

      STERIS (STE) Plans Sale of Non-Core Arm for Debt Repayment

      by Zacks Equity Research

      The latest spin-off of STERIS' (STE) Renal Care business is expected to partly reduce the company's debt burden.

      Is AMN Healthcare Services (AMN) Outperforming Other Medical Stocks This Year?

      by Zacks Equity Research

      Here is how AMN Healthcare Services (AMN) and Apollo Endosurgery, Inc. (APEN) have performed compared to their sector so far this year.

      Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

      by Zacks Equity Research

      Investors are optimistic about Medtronic's (MDT) better-than-expected earnings in the fiscal second quarter and robust performance of the Diabetes arm.

      Bruker (BRKR) Introduces JPK NanoWizard V for AFM Research

      by Zacks Equity Research

      Bruker's (BRKR) newly-introduced JPK NanoWizard V is expected to significantly contribute to life science atomic force microscopy investigations.

      Here's Why You Should Hold on to Alcon (ALC) Stock for Now

      by Zacks Equity Research

      Investors are optimistic about Alcon's (ALC) better-than-expected third-quarter results and robust performance by the Vision Care arm.

      Avantor (AVTR) to Improve Biopharma Supply Chain With New Site

      by Zacks Equity Research

      Avantor's (AVTR) new logistics hub in Westminster is intended to support growth of single-use businesses.